mRNA vs Pox-Vectored Vaccines Against Mpox, Cost-Effectiveness of Prophylactic Use of the Anti-RSV Monoclonal for Infants, and How Molnupiravir Leads to Better Outcomes 3 and 6 Months After Treatment

5 views
September 18, 2024
0 Comments
Login to view comments. Click here to Login